Abstract-Cancer patients often show heterogeneous drug responses such that only a small subset of patients is sensitive to a given anticancer drug. With the availability of large-scale genomic profiling via next-generation sequencing, it is now economically feasible to profile the whole transcriptome and genome of individual patients in order to identify their unique genetic mutations and differentially expressed genes, which are believed to be responsible for heterogeneous drug responses. Although subtyping analysis has identified patient subgroups sharing common biomarkers, there is no effective method to predict the drug response of individual patients precisely and reliably. Herein, we propose a novel computational algorithm to predict the drug response of individual patients based on personal genomic profiles, as well as pharmacogenomic and drug sensitivity data. Specifically, more than 600 cancer cell lines (viewed as individual patients) across over 50 types of cancers and their responses to 75 drugs were obtained from the genomics of drug sensitivity in cancer database. The drug-specific sensitivity signatures were determined from the changes in genomic profiles of individual cell lines in response to a specific drug. The optimal drugs for individual cell lines were predicted by integrating the votes from other cell lines. The experimental results show that the proposed drug prediction algorithm can be used to improve greatly the reliability of finding optimal drugs for individual patients and will, thus, form a key component in the precision medicine infrastructure for oncology care.
cers from the same organ are often quite distinct, as evidenced by the observation that cancer patients with the same cancer type often show heterogeneous responses to the same therapy. It is believed that complex and distinct genomic instability is responsible for the diversity in drug response [1] , [2] . For example, one nonsmall cell lung cancer patient was found to be responsive to Dasatinib dramatically and remained cancer-free for four years later [3] . In the consequent genomic analysis, an inactivating BRAF mutation (Y472C) was found in the patient's tumor, while no inactivating BRAF mutations were found in the nonresponding tumors [3] . The Pan-Cancer project [4] , which aims to analyze the molecular aberrations in cancer cells across a range of tumor types, combines all of the data from different tumor types and enables researchers and scientists to find new patterns of genomic aberrations.
To support studies on uncovering the relationship between the genomic aberrations and diverse drug responses, many valuable large-scale genomic datasets funded by federal agencies have been generated for public access. For example, Cancer Cell Line Encyclopedia (CCLE) [5] and Genomics of Drug Sensitivity in Cancer (GDSC) [6] are two projects that generate such databases and aim to systemically study the causal correlations between drug sensitivity and genomic biomarkers in hundreds of cancer cell lines. Moreover, the connectivity map generated gene expression signature data of different cell lines under various perturbations by more than 1000 small molecules [7] . These data have been scaled since over 1000 times and is publicly available at the library of integrated-network-based cellular signatures (http://www.lincscloud.org/). These large-scale datasets have been used to enable drug repositioning [8] , [9] , predict drug combinations [10] , [11] , and delineate mechanisms of action [12] , and are becoming an important component in drug discovery [13] , [14] . Meanwhile, gene expression omnibus [15] , a public database repository, also archives millions of microarray datasets of various types of cancer under different treatments and perturbations.
Many approaches have been developed to reposition or repurpose known drugs to new indications [16] , [17] , based on the assumption that drugs sharing similar chemical structures would have same targets. With the advance of large-scale genomic profiling techniques, it is economically feasible to profile the whole transcriptome and genome (e.g., microarray, RNAseq, DNAseq, and somatic copy number alterations) [18] [19] [20] of individual patients and identify their unique genetic mutations and differentially expressed genes, which in turn can be used as biomarkers to predict drug sensitivity for those patients. For example, the cancer genome atlas [21] , [22] database repository has collected comprehensive genomics profiles of over 10 000 patient samples covering more than 30 types of cancer. Also, the International Cancer Genome Consortium [23] was formed to coordinate the generation and management of large-scale genomic datasets from over 50 cancer types or subtypes collected from all over the world. These large-scale and comprehensive genomic profiling datasets are invaluable in identifying predictive biomarkers of an individual's drug response, these unique biomarkers can be used for personalized medicine [15] , [24] [25] [26] .
Though subtyping analysis of cancer patients has identified patient subgroups sharing common biomarkers, the genomic instability patterns among the subtypes of a cancer are complex and not easily distinguishable [18] , [22] , [27] [28] [29] . Thus, these genomic patterns derived from the subtyping analysis often fail to offer insight into drug sensitivity and identify reliable predictive biomarkers of individual subtypes. Herein, we propose a novel computational algorithm to predict the optimal drugs for individual patients based on personal genomic profiles, as well as available pharmacogenomics and drug sensitivity information across cancer types. Specifically, 624 cancer cell lines (viewed as individual patients) and their responses to 75 drugs were obtained from GDSC. The drug-specific sensitivity signatures were obtained with the genomics profile changes of individual cell lines. Then, the optimal drug treatments for individual cell lines were predicted by integrating the drug response information from the other cell lines. To test the accuracy of our drug prediction algorithm, we performed twofold cross validation on GDSC dataset and further downloaded 480 cell lines and their responses to 11 drugs from CCLE for validation. The results show that our prediction algorithm can significantly improve the chance of finding sensitive drugs for individual patients.
II. DATA AND METHODOLOGY

A. Data
The simplified molecular-input line-entry system (SMILES) data that describe the structure of compounds using short ASCII strings were downloaded from PubChem (version 2.0.1, 17 October, 2011) [30] . Gene expression data of cell lines and the IC50 data of drugs on the cell lines were downloaded from GDSC (release 4, March 2013) and CCLE (version 2.17, August 2014). Only drugs that have both SMILES and IC50 information, and cell lines that have both IC50 and gene expression profile data were used in our analysis. In summary, IC50 data of 75 drugs on 624 cell lines in GDSC and 24 drugs on 504 cell lines in CCLE were obtained. Fig. 1 shows an overview of the proposed drug prediction algorithm. Let D be the set of known drugs in GDSC, C be the cell line set, and G be the drug-related gene signature consisting of differentially expressed genes between the drug-specific resistant and sensitive cell lines, where n d = |D| , n c = |C| , n g = |G| denoting the number of drugs, cell lines, and genes, respectively. Let A = (a ij ) be the cell line expression matrix, where a ij is the expression value of gene g i ∈ G in cell line c j ∈ C. Let B = (b j k ) be the IC50 value matrix, where b j k is the normalized IC50 value of cell line c j ∈ C treated by drug
B. Algorithm Overview
For each drug-cell line pair, we first calculate similarity scores for pairwise drugs based on their chemical structures and then select most similar drugs to the given one. A gene signature is calculated based on the IC50 values of the selected drugs and gene expression profiles of the cell lines. A flexible similarity score between cell lines was calculated based on the gene signature, and finally, we assign a drug-cell line effect score by combining drug-similarity scores and cell line similarity scores. Using this method, we predicted the top candidate drugs that have the best sensitivity for the given cell line.
C. IC50 Value Normalization
As suggested by GDSC, cell lines with IC50 values greater than the maximum concentration of a drug are likely to be resistant to that drug, while those with IC50 values smaller than maximum concentration are likely to be sensitive. So we divide the raw IC50 value by the maximum concentration of d k ∈ D and then log2-transform it as normalized IC50 value. For drugcell line pairs that lack IC50 values from GDSC, we set their normalized IC50 to 0. Cell lines with a normalized IC50 value greater than 0 are considered to be resistant cell lines to the drug, while others with normalized IC50 value smaller than 0 were considered to be sensitive. As the range of IC50 values of sensitive cell lines differs from the range of resistant cells, we further scaled the normalized IC50 value to the range of [−1,1] for the following analysis.
D. Drug-Drug Similarity
Given two drugs d k 1 ∈ D and d k 2 ∈ D, the "rcdk" R package [31] is used to retrieve their fingerprint information fp k 1 and fp k 2 from the SMILES data. The similarity between the two drugs,
, is calculated using Tanimoto coefficient
where c is the number of fingerprints that appear in both fp k 1 (fingerprints of d k 1 by using the "fingerprint" R package) and fp k 2 (fingerprints of d k 2 ), a is the number of fingerprints that only appear in fp k 1 , and b is the number of fingerprints that only appear in fp k 2 .
E. Patient-Patient Genomics Similarity
Even if two cell lines (or patient cells) share similar overall gene expression signatures, they might still have different drugtreatment response due to the variability in gene expressions of the drug-resistance-related genes. Here, we propose a new method of calculating the cell line similarity scores based on drug-specific-related genes, i.e., different similarity scores are given to each pair of cell lines for different drugs as follows.
For a given drug d given ∈ D, to calculate cell line similarity, we first calculate the drug-drug similarities, is greater than 0, c j is assigned to group 1 (the resistant group); whereas, the others with b j t < 0 are assigned to group 2 (the sensitive group). For each gene g i , we calculate its fold change between the mean expression levels of the two groups, Fold(g i ) = < a i1j 1 , a i2j 1 , . . . , a ik j 1 >(a ij 1 ) and  < a i1j 2 , a i2j 2 , . . . , a ik j 2 > a ij 2 , where g i ∈ G(d given ). To be consistent to the drug-drug similarity score, we scale S (c j 1 , c j 2 ) to [0, 1]. Given a cell line c given , the top r c cell lines that are most similar to it are selected as C c g iv e n .
F. Drug-Patient Similarity
Given the gene expression profile of a patient, we rank the effects of all drugs in GDSC on this patient by defining the drug-patient effect score S(d given , c given ). We first find D d g iv e n to include top r d drugs that are most similar to d given and C c g iv e n to include top r c cell lines that are most similar to c given . Then, the drug-patient effect score is defined by
III. RESULTS
The raw IC50 values for 75 drugs on 624 cell lines from GDSC and their cell line expression profiles were collected, and normalized as described in Section II. Fig. 2 shows the heatmap of the normalized IC50 values (column scaled). The normalized IC50 values were further scaled to [−1, 1] (−1 means the most sensitive, and 1 means the most resistant) for the subsequent analysis. We selected the top 1% genes (about 300 genes) with the largest or smallest fold change between the resistant group and sensitive group as the gene expression signature of individual drugs. Fig. 3 shows the distinct gene expression signatures of AICAR and Dasatinib. To predict the effectiveness between a given cell line and a given drug, the top r d most similar drugs and r c cell lines were tested. Finally, we assigned a similarity score for each drug-cell line (patient) pair. Given a new cell line, the top ranked drugs were considered to be the best candidates.
We have conducted two new validation strategies to reduce the bias in validation and for selecting optimal values for r d and r c . The first one is to use twofold cross validation for modeling GDSC dataset, and the second one is to use GDSC dataset as the training set and CCLE dataset as the independent testing set. First, we apply twofold cross validation on GDSC dataset, i.e., randomly divide the cell lines into two subgroups, with equal size and each time use one as training set and the other as testing set. The testing results are then averaged for each r d and r c . The drug responses on the testing set were estimated using drug treated IC50 values on the training set. Top ten prioritized drugs for each testing cell line were selected. All the drugs were ranked in increasing order based on their normalized IC50 values on the given cell line. We then calculated the enrichment score of the ten drugs in the ordered drug list using the gene set enrichment analysis (GSEA) [32] , denoted as ES cl . The enrichment score, ES cl , which ranges from −1 to 1, and would be close to 1 if the selected drugs were found at the top of the ranked drug list and vice versa. To test whether our selected drugs for the given cell line ranked higher than random selection, we randomly selected ten drugs for each cell line for 5000 times and recalculated the enrichment score, denoted by ES i , i = 1, . . . , 5000. The p value was calculated as 5 0 0 0
Small p value (here we set the threshold as p < 0.05) means that the prediction can discover the more sensitive drugs to the given cell line, compared with the random selection. The percentage of cell lines with corresponding p value <0.05 were then averaged (twofold cross validation) to for each r d = [1, . . . , 4] and r c =  [1, . . . , 10] . The results were shown in Fig. 4 . As can be seen, the prediction power of single drug (r d = 1) decreases when more similar cell lines being added (noise sensitive), whereas, the prediction power with multiple similar drugs increases with more similar cell lines (noise robust). Especially, the parameter setting r d = 3 and r c = 9 generates the best prediction power.
Moreover, the CCLE datasets were also collected for the validation. There are 11 drugs in both GDSC and CCLE database. We use GDSC data as the training set, and download drug treated IC50 values for 480 cell lines of the 11 drugs from CCLE database as the testing dataset. We then predict the drug responses on 480 cell lines in CCLE for 11 drugs. Since there are only 11 drugs available, it is hard to find sensitive drugs for each cell line. We, thus, select top 10 drug-cell line pairs predicted using our model and compare their IC50 values in CCLE with all other drug-cell line IC50 values. Then, p values were calculated for each r d and r c using GSEA as described above. The results were shown in Table I . As we can see, the p values are smaller than 0.05 in almost all the cases, which means the top 10 drug-cell line pairs predicted by our model have a much lower IC50 value compared with random selection, and thus, the cell lines are more sensitive to these drugs. Note that the p value for r d = 3 and r c = 9 was smaller than 4e-4. By considering both validation methods, we suggest to use r d = 3 and r c = 9 in our model. In summary, the proposed prediction algorithm can improve the effective drug selection significantly, and the evaluation results indicate the possibility of selecting the optimal drugs among all anticancer drugs based on their genomic profiles to achieve better therapeutic outcomes.
IV. DISCUSSION
It is difficult to determine "sensitive" responses to drugs. We use normalized IC50 score to measure the cell line sensitivity based on the documents of GDSC, which suggest that cell lines with acute drug response, IC50 < max drug concentration, and small confidence intervals are supposed to be sensitive to drugs. In the latest release of GDSC (release 5, June 2014), a Z-score is calculated for each cell line to define "sensitive" and "resistance" to drugs. Both measurements should be fine and people can also use other drug response data to replace the normalized IC50 values in our algorithm.
There also exist other algorithms to find differentially expressed genes between sensitive groups and resistant groups. We first tested if t-test could be used to find drug signatures. We did Shapiro-Wilk test on the expression values of genes across cell lines and found that the expression value of most of the genes (over 10 000) did not form normal distribution. Thus, t-test and other similar methods such as SAMR were not suitable here. Then, we tested Wilcoxon rank sum test which was a nonparametric statistic test followed by the Benjamini and Hochberg method (Journal of the Royal Statistical Society Series B, 57, 289-300, 1995) to control false discovery rate. Genes with adjusted p value <0.05 were selected as drug signature. However, the number of differentially expressed genes varies significantly from tens to thousands; furthermore, the drug prediction result is worse than using the top 1% fold change genes. One possible reason is that the sample size of sensitive cell lines for each drug is usually too small (less than 10) to provide sufficient power for statistic testing.
V. CONCLUSION
Patients with the same type of cancer often respond differently to the same drug treatment, and only a small subset of patients has profound sensitivity to the given drugs. The complex and distinct genomic instability of individual cancer patients is believed to be responsible for that diversity in drug response. Due to recent advances made in the next-generation sequencing, large-scale pharmacogenomic databases are now publicly available, while genomic profiling of individual patients is becoming economically affordable. It is timely to leverage such information to predict the drug sensitivity for each patient in order to achieve the optimal personalized treatment. However, computational analysis is the bottleneck in associating the complex genomic profiles reliably with heterogeneous drug responses.
Motivated by the public availability of informative data resources, this study contributed a computational algorithm for predicting the best drugs for individual cell lines (representing individual patients) based on their genomic profiles and drug response data. Our cross validation showed that the best drug prediction results on over 40% cell lines are improved significantly compared to random selection. Moreover, the results from CCLE validation showed that the top ten most sensitive drug-cell line pairs predicted by our model using GDSC database have significant lower IC50 values than others. Our research finding suggests the potential of selecting optimal drugs among anticancer drugs for individual patients based on their genomic profiles, which will impact the cancer clinical regimen profoundly. Our ongoing work of integrating the drug prediction algorithm into the precision medicine framework being developed at Houston Methodist Cancer Center to investigate personal genomic profiles from patients, evaluate the prediction results on patient-derived xenograft models, and track the predictive performance on selected patients under treatment at Houston Methodist Hospital.
